| Literature DB >> 24534843 |
Kwaku Kyeremeh1, Kojo Sekyi Acquah2, Anil Sazak3, Wael Houssen4, Jioji Tabudravu5, Hai Deng6, Marcel Jaspars7.
Abstract
A new actinomycete strain Micromonospora sp. K310 was isolated from Ghanaian mangrove river sediment. Spectroscopy-guided fractionation led to the isolation of two new compounds from the fermentation culture. One of the compounds is butremycin (2) which is the (3-hydroxyl) derivative of the known Streptomyces metabolite ikarugamycin (1) and the other compound is a protonated aromatic tautomer of 5'-methylthioinosine (MTI) (3). Both new compounds were characterized by 1D, 2D NMR and MS data. Butremycin (2) displayed weak antibacterial activity against Gram-positive S. aureus ATCC 25923, the Gram-negative E. coli ATCC 25922 and a panel of clinical isolates of methicillin-resistant S. aureus (MRSA) strains while 3 did not show any antibacterial activity against these microbes.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24534843 PMCID: PMC3944527 DOI: 10.3390/md12020999
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Characteristic ring sequences for polycyclic tetramic acid macrolactams (PTM) compounds isolated to date including ikarugamycin and butremycin.
Figure 2Neighbor-joining tree [10] based on almost complete 16 rDNA gene sequences (1455 nt) showing the position of Micromonospora sp. K310 (KF803252) amongst its phylogenetic neighbors. Catellatospora citrea DSM 44097T (GenBank accession no. X93197) was used as an out-group. Numbers at nodes indicate the levels of bootstrap support (%); only values >50% are shown. GenBank accession numbers are given in parentheses. Bar, 0.005 substitutions per site.
Figure 3(a) Selected COSY (▬) and gHMBCAD (→) data for butremycin; (b) Selected ROESY (↔) data for butremycin (2).
1H and 13CNMR data of butremycin in CD3OD. δ in ppm, J in Hz.
| Position | δH mult ( | δC mult | HMBC |
|---|---|---|---|
| 1 | 195.5, C | 2 | |
| 2 | 3.70, d (2.4) | 68.4, CH | |
| 3 | 3.86, ddd (7.2, 1.9, 1.9) | 72.5, CH | 2, 4, 5 |
| 4 | 1.51, m; 1.24, m | 32.1, CH2 | 2, 3 |
| 5 | 3.42, m; 2.71, t (12.0) | 37.9, CH2 | 3 |
| 6-NH | 8.43, s | ||
| 7 | 168.9, C | 5, 8, 9 | |
| 8 | 5.76, dd (11.4, 2.8) | 124.8, CH | 10 |
| 9 | 6.02, ddd (11.4, 11.4, 2.6) | 141.8, CH | 10 |
| 10 | 3.53, m; 2.09, m | 25.9, CH2 | 8 |
| 11 | 1.35, m | 50.3, CH | 9, 10, 20, 22, 23 |
| 12 | 2.51, m | 43.4, CH | 10, 14 |
| 13 | 5.62, ddd (9.9, 2.8, 2.8) | 129.6, CH | |
| 14 | 5.83, dt (10.0, 2.1) | 131.9, CH | |
| 15 | 1.48, m | 48.4, CH | 13, 14, 19 |
| 16 | 1.29, m | 48.5, CH | 17, 30 |
| 17 | 2.20, m | 34.3, CH | 18, 29, 30 |
| 18 | 2.05, m; 0.63, ddd (11.9, 11.8, 6.8) | 39.9, CH2 | 19, 29 |
| 19 | 1.08, m | 50.4, CH | 14, 18, 21 |
| 20 | 2.00, m | 43.2, CH | 13, 18, 21 |
| 21 | 2.01, m; 1.10, m | 38.1, CH2 | 19, 22, 23 |
| 22 | 2.32, m | 49.6, CH | 21, 23, 24 |
| 23 | 6.47, dd (15.1, 10.0) | 147.8, CH | 21, 22 |
| 24 | 7.30, d (15.2) | 130.4, CH | 22 |
| 25 | 184.7, C | 23, 24 | |
| 26 | 102.8, C | ||
| 27 | 179.9, C | 2 | |
| 28-NH | 8.43, s | ||
| 29 | 0.81, d (6.0) | 18.1, CH3 | 17, 18 |
| 30 | 1.42, m; 1.30, m | 22.7, CH2 | 16, 31 |
| 31 | 0.87, t (7.1) | 13.7, CH3 | 30 |
Figure 4Selected COSY (▬) and gHMBCAD (→) data for compound 3.
1H and 13C NMR data of compound 3 in CD3OD. δ in ppm, J in Hz.
| Position | δH mult ( | δC mult | HMBC |
|---|---|---|---|
| 1-N | |||
| 2 | 8.07, s | 146.8, CH | |
| 3-NH | 8.29, s | ||
| 4 | 150.2, C | 2, NH-3,1′ | |
| 5 | 125.8, C | 2, NH-3 | |
| 6 | 158.9, C | 2 | |
| 7-N | |||
| 8 | 140.9, CH | 1′ | |
| 9-N | |||
| 1′ | 6.02, d (4.8) | 90.2, CH | 2′,3′ |
| 2′ | 4.73, t (5.1) | 75.2, CH | 1′ |
| 3′ | 4.32, t (4.8) | 73.9, CH | 4′,5′ |
| 4′ | 4.22, q (5.4) | 85.6, CH | 2′,5′ |
| 5′ | 2.93, dd (14.1, 5.5) 2.873, dd (14.1, 5.9) | 37.5, CH2 | 3′,7′ |
| 6′-S | |||
| 7′ | 2.14, s | 16.5, CH3 | 5′ |
Scheme 1Possible biosynthetic origin of compound (3) showing 5′-methylthioadenosine (MTA) degradation pathways in Phyla Bacteria, Eucarya and Archaea and Pseudomonas aeruginosa.
Antibacterial activity of butremycin against Staphylococcus aureus ATCC25923, Escherichia coli ATCC 25922 and a selection of methicillin-resistant Staphylococcus aureus (MRSA) strains.
| Strain | Source of Isolate | MIC (µg mL−1) | |
|---|---|---|---|
| Butremycin | Rifampicin | ||
| ATCC | 50 | 0.003 | |
| ATCC | 50 | 0.01 | |
| SMRSA 105 | Toe wound | >50 | 0.007 |
| SMRSA 124 | Open wound | >50 | 0.03 |
| SMRSA 116 | Knee abscess | >50 | 0.01–0.03 |
| EMRSA 15 | Urine infection | 50 | 0.001–0.003 |
a Laboratory strains; All clinical isolates were obtained from the NHS Grampian Microbiology Diagnostic Laboratory, Aberdeen Royal infirmary; Abbreviations: EMSRA = epidemic MRSA, SMRA = Scottish MRSA.